<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01010971</url>
  </required_header>
  <id_info>
    <org_study_id>060-634</org_study_id>
    <nct_id>NCT01010971</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older</brief_title>
  <official_title>A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol (160 μg Once Daily and 80 μg Once Daily) for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical research study will evaluate the safety and effectiveness of two doses of an
      investigational medication (ciclesonide nasal aerosol) for the treatment of subjects with of
      seasonal allergic rhinitis (SAR). The study will consist of a Screening Period to confirm
      study eligibility, followed by a Single-Blind Placebo Run-in period to acclimate subjects to
      the proper use of the study medication and to assess the subject's severity of SAR symptoms,
      followed by a 2-week double-blind treatment period to assess the safety and effectiveness of
      the study medication when given to eligible subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, parallel group, multicenter study.
      This study will consist of a Screening Period, followed by a Single-Blind Placebo Run-in
      period. The Double-blind Treatment period (14±2 days) will begin at randomization/Day 1 and
      consist of an interim visit 7±1 days after randomization, and an End of Study (EOS)/Early
      Termination (ET) visit. All subjects will have either a telephone contact, or in some cases
      an in-clinic visit, 7±2 days after their last study visit. This study was previously posted
      by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma.,
      and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM and PM Reflective TNSS Averaged Over the Two-week Treatment Period.</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM and PM Instantaneous TNSS Averaged Over the 2-week Treatment Period.</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM and PM Reflective TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the RQLQ(S) Overall Score at the End of the 2-week Treatment Period in Impaired Subjects With Baseline RQLQ(S) Score of ≥3.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>RQLQ(S) in impaired subjects with baseline RQLQ[S] score ≥3.0. RQLQ(S) consists of 28 questions, each question measured on a scale of 0-6 where a higher score indicates poor quality of life. Domains: Activities (questions 1-3), Sleep (questions 4-6), Non-Nose/Eye Symptoms (questions 7-13), Practical Problems (questions 14-16), Nasal Symptoms (questions 17-20), Eye Symptoms (questions 21-24), and Emotional (questions 25-28). The overall RQLQ(S) score was calculated as the average of the mean domain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM Reflective TNSS Averaged Over the 2-week Treatment Period.</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported PM Reflective TNSS Averaged Over the 2 Week Treatment Period.</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM Instantaneous TNSS Averaged Over the 2-week Treatment Period.</measure>
    <time_frame>Week0-2</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported PM Instantaneous TNSS Averaged Over the 2-week Treatment Period.</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM Reflective TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported PM Reflective TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM Instantaneous TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0.</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported PM Instantaneous TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0.</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM and PM Instantaneous TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0.</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported Individual AM Instantaneous NSS Averaged Over the 2-week Treatment Period</measure>
    <time_frame>Week 0-2</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported Individual PM Instantaneous NSS Averaged Over the 2-week Treatment Period</measure>
    <time_frame>Week 0-2</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported Individual AM and PM Instantaneous NSS Averaged Over the 2-week Treatment Period</measure>
    <time_frame>Week 0-2</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported Individual AM Reflective Nasal Symptom Scores (NSS) Averaged Over the 2-week Treatment Period.</measure>
    <time_frame>Week 0-2</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported Individual PM Reflective NSS Averaged Over the 2-week Treatment Period.</measure>
    <time_frame>Week 0-2</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported Individual AM and PM Reflective NSS Averaged Over the 2-week Treatment Period.</measure>
    <time_frame>Week 0-2</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported Individual AM Instantaneous OSS in Subjects With Baseline TOSS≥5.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Instantaneous OSS measures these symptoms over the previous 10 minute time interval. iTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported Individual PM Instantaneous OSS in Subjects With Baseline TOSS≥5.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Instantaneous OSS measures these symptoms over the previous 10 minute time interval. iTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported Individual AM and PM Instantaneous OSS in Subjects With Baseline TOSS≥5.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Instantaneous OSS measures these symptoms over the previous 10 minute time interval. iTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported Individual AM Reflective OSS in Subjects With Baseline TOSS ≥5.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective OSS measures these symptoms over the previous 12-hour time interval. rTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported Individual PM Reflective OSS in Subjects With Baseline TOSS ≥5.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective OSS measures these symptoms over the previous 12-hour time interval. rTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported Individual AM and PM Reflective OSS in Subjects With Baseline TOSS ≥5.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective OSS measures these symptoms over the previous 12-hour time interval. rTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the RQLQ(S) Domains at the End of the 2-week Treatment Period in Impaired Subjects With Baseline RQLQ(S) Score of ≥3.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>RQLQ(S) in subjects with baseline RQLQ[S] score ≥3.0. RQLQ(S) consists of 28 questions, each question measured on a scale of 0-6 where a higher score indicates poor quality of life. Domains: Activities (questions 1-3), Sleep (questions 4-6), Non-Nose/Eye Symptoms (questions 7-13), Practical Problems (questions 14-16), Nasal Symptoms (questions 17-20), Eye Symptoms (questions 21-24), and Emotional (questions 25-28). The overall RQLQ(S) score was calculated as the average of the mean domain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximal Effect Over the 2-week of Double-blind Treatment Period.</measure>
    <time_frame>Week 0-2</time_frame>
    <description>The time to maximal effect is defined as the number of days until the first treatment day on which the estimated difference between Ciclesonide HFA and placebo is at least 90% of the largest estimated difference. This is based on the analyses of change from baseline in the average of AM and PM reflective TNSS scores for each day. The evaluation is made separately for each dose level of Ciclesonide HFA compared to placebo.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">671</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Ciclesonide HFA Nasal Aerosol 160 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>160 μg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciclesonide HFA Nasal Aerosol 80 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 μg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide HFA 160 μg</intervention_name>
    <description>Ciclesonide HFA Nasal Aerosol 160 μg once daily</description>
    <arm_group_label>Ciclesonide HFA Nasal Aerosol 160 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide HFA 80 μg</intervention_name>
    <description>Ciclesonide HFA Nasal Aerosol 80 μg once daily</description>
    <arm_group_label>Ciclesonide HFA Nasal Aerosol 80 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo HFA Nasal Aerosol once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Give written informed consent, including privacy authorization as well as adherence to
             concomitant medication withholding periods, prior to participation.

          -  Subject must be in general good health (defined as the absence of any clinically
             relevant abnormalities as determined by the Investigator) based on screening physical
             examination, medical history, and clinical laboratory values (Hematology, Chemistries
             and Urinalysis). If any of the Hematology, Chemistries, or Urinalysis are not within
             the clinical laboratory's reference range, then the subject can be included only if
             the Investigator judges the deviations to be not clinically significant.

          -  A history of SAR to Mountain Cedar for a minimum of two years immediately preceding
             the study Screening Visit. The SAR must have been of sufficient severity to have
             required treatment (either continuous or intermittent) in the past and in the
             Investigator's judgment (through exposure to allergen) is expected to require
             treatment throughout the entire study period.

          -  A demonstrated sensitivity to Mountain Cedar known to induce SAR through a standard
             skin prick test administered at screening. A positive test is defined as a wheal
             diameter at least 5 mm larger than the control wheal (normal saline) for the skin
             prick test.

          -  Subject, if female 65 years of age or younger, must have a negative serum pregnancy
             test. Females of childbearing potential must be instructed to and agree to avoid
             pregnancy during the study and must use an acceptable method of birth control: An oral
             contraceptive, an intrauterine device (IUD), implantable contraceptive, transdermal or
             injectable contraceptive for at least 1 month prior to entering the study and will
             continue its use throughout the study and for thirty days following study
             participation; Barrier method of contraception, eg, condom and/or diaphragm with
             spermicide while participating in the study; Abstinence.

          -  Subject or parent/guardian must possess an educational level and degree of
             understanding of English that enables them to communicate suitably with the
             Investigator and study coordinator as well as accurately complete both the AR diary
             and RQLQ(S).

        Exclusion Criteria:

          -  Female subject who is pregnant or lactating.

          -  History of physical findings of nasal pathology, including nasal polyps or other
             clinically significant respiratory tract malformations; recent nasal biopsy; nasal
             trauma; nasal ulcers or perforations; or surgery and atrophic rhinitis or rhinitis
             medicamentosa (all within the last 60 days prior to the Screening Visit).

          -  Participation in any investigational drug trial within the 30 days preceding the
             Screening Visit or planned participation in another investigational drug trial at any
             time during this trial.

          -  A known hypersensitivity to any corticosteroid or any of the excipients in the
             formulation of ciclesonide.

          -  History of a respiratory infection or disorder [including, but not limited to
             bronchitis, pneumonia, chronic sinusitis, influenza, severe acute respiratory syndrome
             (SARS)] within the 14 days preceding the Screening Visit .

          -  History of alcohol or drug abuse within two years preceding the Screening Visit.

          -  History of a positive test for HIV, hepatitis B or hepatitis C.

          -  Plans to travel outside the study area (the known pollen area for the investigative
             site) for more than 24 hours during the Run-in period.

          -  Plans to travel outside the study area (the known pollen area for the investigative
             site) for 2 or more consecutive days between Randomization Visit and the final
             Treatment Visit.

          -  Active asthma requiring treatment with inhaled or systemic corticosteroids and/or
             routine use of beta-agonists and any controller drugs (eg, theophylline, leukotriene
             antagonists, etc.); intermittent use (less than or equal to 3 uses per week) of
             inhaled short acting beta-agonists is acceptable.

          -  Use of any disallowed concomitant medications within the prescribed (per protocol)
             time period prior to the Screening Visit and expected use during treatment period.

          -  Use of antibiotic therapy for acute conditions within 14 days prior to the Screening
             Visit. Low doses of antibiotics taken for prophylaxis are permitted if the therapy was
             started prior to the Screening Visit and is expected to continue throughout the trial.

          -  Initiation of immunotherapy during the study period or dose escalation during the
             study period. However, initiation of immunotherapy 90 days or more prior to the
             Screening Visit and use of a stable (maintenance) dose (30 days or more) may be
             considered for inclusion.

          -  Previous participation in an intranasal ciclesonide HFA nasal aerosol study.

          -  Non-vaccinated exposure to or active infection with, chickenpox or measles within the
             21 days preceding the Screening Visit.

          -  Initiation of pimecrolimus cream 1% or greater or tacrolimus ointment 0.03% or greater
             during the study period or planned dose escalation during the study period. However,
             initiation of these creams/ointments 30 days or more prior to screening and use of a
             stable (maintenance) dose during the study period may be considered for inclusion.

          -  Study participation by clinical investigator site employees and/or their immediate
             relatives.

          -  Study participation by more than one subject from the same household at the same time.

          -  Have any of the following conditions that are judged by the investigator to be
             clinically significant and/or affect the subject's ability to participate in the
             clinical trial:

               -  impaired hepatic function including alcohol-related liver disease or cirrhosis;

               -  history of ocular disturbances eg, glaucoma or posterior subcapsular cataracts;

               -  any systemic infection;

               -  hematological, hepatic, renal, endocrine (except for controlled diabetes mellitus
                  or postmenopausal symptoms or hypothyroidism);

               -  gastrointestinal disease;

               -  malignancy (excluding basal cell carcinoma);

               -  current neuropsychological condition with or without drug therapy.

          -  Any condition that, in the judgement of the investigator, would preclude the subject
             from completing the protocol with capture of the assessments as written.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Allergy and Asthma Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinus Clinical Research LLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Health Research Corporation</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biogenics Research Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Allergy and Asthma Research Center, Pa</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvana Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ratner PH, Andrews C, Martin B, Howland W, Desai SY, Huang H, Hinkle J, Bode F. A study of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol in patients with seasonal allergic rhinitis from mountain cedar pollen. Allergy Asthma Proc. 2012 Jan-Feb;33(1):27-35. doi: 10.2500/aap.2012.33.3490.</citation>
    <PMID>22370531</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2009</study_first_submitted>
  <study_first_submitted_qc>November 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2009</study_first_posted>
  <results_first_submitted>February 15, 2012</results_first_submitted>
  <results_first_submitted_qc>May 7, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 8, 2012</results_first_posted>
  <disposition_first_submitted>September 17, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 17, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 21, 2010</disposition_first_posted>
  <last_update_submitted>June 8, 2012</last_update_submitted>
  <last_update_submitted_qc>June 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mountain Cedar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciclesonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
          <description>160 μg once daily</description>
        </group>
        <group group_id="P2">
          <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
          <description>80 μg once daily</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="225"/>
                <participants group_id="P2" count="226"/>
                <participants group_id="P3" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="222"/>
                <participants group_id="P2" count="218"/>
                <participants group_id="P3" count="207"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
          <description>160 μg once daily</description>
        </group>
        <group group_id="B2">
          <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
          <description>80 μg once daily</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo once daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="225"/>
            <count group_id="B2" value="226"/>
            <count group_id="B3" value="220"/>
            <count group_id="B4" value="671"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="202"/>
                    <measurement group_id="B4" value="594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.4" spread="14.4"/>
                    <measurement group_id="B2" value="39.8" spread="14.7"/>
                    <measurement group_id="B3" value="41.0" spread="13.5"/>
                    <measurement group_id="B4" value="40.4" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98" spread="43.6"/>
                    <measurement group_id="B2" value="89" spread="39.4"/>
                    <measurement group_id="B3" value="100" spread="45.5"/>
                    <measurement group_id="B4" value="287" spread="42.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127" spread="56.4"/>
                    <measurement group_id="B2" value="137" spread="60.6"/>
                    <measurement group_id="B3" value="120" spread="54.5"/>
                    <measurement group_id="B4" value="384" spread="57.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White/Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="191"/>
                    <measurement group_id="B3" value="191"/>
                    <measurement group_id="B4" value="589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiin or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Reflective Total Nasal Symptom Score (rTNSS)</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>AM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.33" spread="1.78"/>
                    <measurement group_id="B2" value="9.47" spread="1.80"/>
                    <measurement group_id="B3" value="9.34" spread="1.76"/>
                    <measurement group_id="B4" value="9.38" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.20" spread="1.97"/>
                    <measurement group_id="B2" value="9.21" spread="2.11"/>
                    <measurement group_id="B3" value="9.21" spread="1.92"/>
                    <measurement group_id="B4" value="9.21" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.26" spread="1.80"/>
                    <measurement group_id="B2" value="9.34" spread="1.88"/>
                    <measurement group_id="B3" value="9.28" spread="1.77"/>
                    <measurement group_id="B4" value="9.29" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Instantaneous Total Nasal Symptom Score (iTNSS)</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>AM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.77" spread="2.10"/>
                    <measurement group_id="B2" value="8.73" spread="2.18"/>
                    <measurement group_id="B3" value="8.69" spread="2.19"/>
                    <measurement group_id="B4" value="8.73" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.51" spread="2.29"/>
                    <measurement group_id="B2" value="8.49" spread="2.35"/>
                    <measurement group_id="B3" value="8.36" spread="2.38"/>
                    <measurement group_id="B4" value="8.45" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.64" spread="2.14"/>
                    <measurement group_id="B2" value="8.60" spread="2.15"/>
                    <measurement group_id="B3" value="8.53" spread="2.21"/>
                    <measurement group_id="B4" value="8.59" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Baseline Reflective Ocular Symptom Score (rTOSS) in Subjects with rTOSS ≥5.0</title>
          <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>AM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.09" spread="1.24"/>
                    <measurement group_id="B2" value="7.17" spread="1.24"/>
                    <measurement group_id="B3" value="6.99" spread="1.21"/>
                    <measurement group_id="B4" value="7.09" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.00" spread="1.30"/>
                    <measurement group_id="B2" value="7.10" spread="1.25"/>
                    <measurement group_id="B3" value="6.94" spread="1.30"/>
                    <measurement group_id="B4" value="7.01" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.04" spread="1.22"/>
                    <measurement group_id="B2" value="7.13" spread="1.19"/>
                    <measurement group_id="B3" value="6.97" spread="1.19"/>
                    <measurement group_id="B4" value="7.05" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Instantaneous Total Ocular Symtom Score (iTOSS) in Subjects with iTOSS ≥5.0</title>
          <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>AM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.07" spread="1.20"/>
                    <measurement group_id="B2" value="7.07" spread="1.26"/>
                    <measurement group_id="B3" value="7.05" spread="1.14"/>
                    <measurement group_id="B4" value="7.06" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.90" spread="1.35"/>
                    <measurement group_id="B2" value="6.88" spread="1.39"/>
                    <measurement group_id="B3" value="6.92" spread="1.20"/>
                    <measurement group_id="B4" value="6.90" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.99" spread="1.21"/>
                    <measurement group_id="B2" value="6.97" spread="1.24"/>
                    <measurement group_id="B3" value="6.99" spread="1.07"/>
                    <measurement group_id="B4" value="6.98" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Reflective Nasal Symptom Score (rNSS)</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization.</description>
          <units>unit on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>AM sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.04" spread="0.71"/>
                    <measurement group_id="B2" value="2.10" spread="0.74"/>
                    <measurement group_id="B3" value="2.06" spread="0.70"/>
                    <measurement group_id="B4" value="2.07" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM runny nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.43" spread="0.54"/>
                    <measurement group_id="B2" value="2.43" spread="0.57"/>
                    <measurement group_id="B3" value="2.42" spread="0.55"/>
                    <measurement group_id="B4" value="2.43" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM nasal itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.29" spread="0.59"/>
                    <measurement group_id="B2" value="2.38" spread="0.54"/>
                    <measurement group_id="B3" value="2.31" spread="0.59"/>
                    <measurement group_id="B4" value="2.33" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM nasal congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.57" spread="0.41"/>
                    <measurement group_id="B2" value="2.56" spread="0.46"/>
                    <measurement group_id="B3" value="2.55" spread="0.45"/>
                    <measurement group_id="B4" value="2.56" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.06" spread="0.68"/>
                    <measurement group_id="B2" value="2.10" spread="0.75"/>
                    <measurement group_id="B3" value="2.10" spread="0.69"/>
                    <measurement group_id="B4" value="2.09" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM runny nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.40" spread="0.59"/>
                    <measurement group_id="B2" value="2.34" spread="0.63"/>
                    <measurement group_id="B3" value="2.35" spread="0.59"/>
                    <measurement group_id="B4" value="2.36" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM nasal itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.27" spread="0.62"/>
                    <measurement group_id="B2" value="2.30" spread="0.60"/>
                    <measurement group_id="B3" value="2.27" spread="0.60"/>
                    <measurement group_id="B4" value="2.28" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM nasal congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.47" spread="0.49"/>
                    <measurement group_id="B2" value="2.47" spread="0.52"/>
                    <measurement group_id="B3" value="2.48" spread="0.50"/>
                    <measurement group_id="B4" value="2.48" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.05" spread="0.66"/>
                    <measurement group_id="B2" value="2.10" spread="0.72"/>
                    <measurement group_id="B3" value="2.08" spread="0.67"/>
                    <measurement group_id="B4" value="2.08" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM runny nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.41" spread="0.54"/>
                    <measurement group_id="B2" value="2.38" spread="0.57"/>
                    <measurement group_id="B3" value="2.39" spread="0.55"/>
                    <measurement group_id="B4" value="2.39" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM nasal itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.28" spread="0.59"/>
                    <measurement group_id="B2" value="2.34" spread="0.55"/>
                    <measurement group_id="B3" value="2.29" spread="0.57"/>
                    <measurement group_id="B4" value="2.30" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM nasal congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.52" spread="0.43"/>
                    <measurement group_id="B2" value="2.52" spread="0.47"/>
                    <measurement group_id="B3" value="2.52" spread="0.45"/>
                    <measurement group_id="B4" value="2.52" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Instantaneous Nasal Symptom Score (iNSS)</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization.</description>
          <units>unit on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>AM sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.73" spread="0.84"/>
                    <measurement group_id="B2" value="1.75" spread="0.91"/>
                    <measurement group_id="B3" value="1.73" spread="0.88"/>
                    <measurement group_id="B4" value="1.74" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM runny nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.32" spread="0.58"/>
                    <measurement group_id="B2" value="2.26" spread="0.64"/>
                    <measurement group_id="B3" value="2.29" spread="0.64"/>
                    <measurement group_id="B4" value="2.29" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM nasal itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.22" spread="0.66"/>
                    <measurement group_id="B2" value="2.23" spread="0.64"/>
                    <measurement group_id="B3" value="2.20" spread="0.68"/>
                    <measurement group_id="B4" value="2.22" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM nasal congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.50" spread="0.47"/>
                    <measurement group_id="B2" value="2.48" spread="0.51"/>
                    <measurement group_id="B3" value="2.47" spread="0.53"/>
                    <measurement group_id="B4" value="2.48" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.79" spread="0.82"/>
                    <measurement group_id="B2" value="1.79" spread="0.89"/>
                    <measurement group_id="B3" value="1.77" spread="0.88"/>
                    <measurement group_id="B4" value="1.78" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM runny nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.22" spread="0.65"/>
                    <measurement group_id="B2" value="2.18" spread="0.69"/>
                    <measurement group_id="B3" value="2.16" spread="0.70"/>
                    <measurement group_id="B4" value="2.19" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM nasal itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.13" spread="0.68"/>
                    <measurement group_id="B2" value="2.17" spread="0.66"/>
                    <measurement group_id="B3" value="2.10" spread="0.69"/>
                    <measurement group_id="B4" value="2.13" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM nasal congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.36" spread="0.54"/>
                    <measurement group_id="B2" value="2.36" spread="0.57"/>
                    <measurement group_id="B3" value="2.34" spread="0.55"/>
                    <measurement group_id="B4" value="2.35" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.76" spread="0.81"/>
                    <measurement group_id="B2" value="1.77" spread="0.86"/>
                    <measurement group_id="B3" value="1.75" spread="0.86"/>
                    <measurement group_id="B4" value="1.76" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM runny nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.27" spread="0.60"/>
                    <measurement group_id="B2" value="2.22" spread="0.62"/>
                    <measurement group_id="B3" value="2.23" spread="0.64"/>
                    <measurement group_id="B4" value="2.24" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM nasal itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.18" spread="0.65"/>
                    <measurement group_id="B2" value="2.20" spread="0.61"/>
                    <measurement group_id="B3" value="2.15" spread="0.66"/>
                    <measurement group_id="B4" value="2.17" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM nasal congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.43" spread="0.48"/>
                    <measurement group_id="B2" value="2.42" spread="0.51"/>
                    <measurement group_id="B3" value="2.41" spread="0.51"/>
                    <measurement group_id="B4" value="2.42" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Individual Reflective Ocular Symptom Score (rOSS) in Subjects with (rTOSS) ≥5.0</title>
          <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms.)Reflective OSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization.</description>
          <units>unit on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>AM itching eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.49" spread="0.44"/>
                    <measurement group_id="B2" value="2.52" spread="0.43"/>
                    <measurement group_id="B3" value="2.48" spread="0.44"/>
                    <measurement group_id="B4" value="2.49" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM redness of eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.31" spread="0.57"/>
                    <measurement group_id="B2" value="2.28" spread="0.62"/>
                    <measurement group_id="B3" value="2.24" spread="0.60"/>
                    <measurement group_id="B4" value="2.28" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM tearing eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.30" spread="0.48"/>
                    <measurement group_id="B2" value="2.37" spread="0.51"/>
                    <measurement group_id="B3" value="2.28" spread="0.50"/>
                    <measurement group_id="B4" value="2.31" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM itching eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.47" spread="0.45"/>
                    <measurement group_id="B2" value="2.50" spread="0.47"/>
                    <measurement group_id="B3" value="2.45" spread="0.48"/>
                    <measurement group_id="B4" value="2.47" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM redness of eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.28" spread="0.58"/>
                    <measurement group_id="B2" value="2.26" spread="0.65"/>
                    <measurement group_id="B3" value="2.24" spread="0.62"/>
                    <measurement group_id="B4" value="2.26" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM tearing eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.25" spread="0.56"/>
                    <measurement group_id="B2" value="2.34" spread="0.52"/>
                    <measurement group_id="B3" value="2.25" spread="0.51"/>
                    <measurement group_id="B4" value="2.28" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM itching eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.48" spread="0.43"/>
                    <measurement group_id="B2" value="2.51" spread="0.43"/>
                    <measurement group_id="B3" value="2.46" spread="0.44"/>
                    <measurement group_id="B4" value="2.48" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM redness of eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.29" spread="0.55"/>
                    <measurement group_id="B2" value="2.27" spread="0.62"/>
                    <measurement group_id="B3" value="2.24" spread="0.59"/>
                    <measurement group_id="B4" value="2.27" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM tearing eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.27" spread="0.49"/>
                    <measurement group_id="B2" value="2.35" spread="0.49"/>
                    <measurement group_id="B3" value="2.27" spread="0.48"/>
                    <measurement group_id="B4" value="2.30" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Individual Instantaneous Ocular Symptom Score (iOSS) in subjects with (iTOSS) ≥5.0</title>
          <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous OSS measures these symptoms over the previous 10 minute time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization.</description>
          <units>unit on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>AM itching eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.47" spread="0.43"/>
                    <measurement group_id="B2" value="2.47" spread="0.44"/>
                    <measurement group_id="B3" value="2.45" spread="0.47"/>
                    <measurement group_id="B4" value="2.46" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM redness of eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.34" spread="0.56"/>
                    <measurement group_id="B2" value="2.29" spread="0.60"/>
                    <measurement group_id="B3" value="2.31" spread="0.52"/>
                    <measurement group_id="B4" value="2.31" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM tearing eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.26" spread="0.50"/>
                    <measurement group_id="B2" value="2.32" spread="0.52"/>
                    <measurement group_id="B3" value="2.29" spread="0.45"/>
                    <measurement group_id="B4" value="2.29" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM itching eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.41" spread="0.46"/>
                    <measurement group_id="B2" value="2.40" spread="0.50"/>
                    <measurement group_id="B3" value="2.41" spread="0.47"/>
                    <measurement group_id="B4" value="2.41" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM redness of eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.30" spread="0.58"/>
                    <measurement group_id="B2" value="2.24" spread="0.62"/>
                    <measurement group_id="B3" value="2.28" spread="0.54"/>
                    <measurement group_id="B4" value="2.27" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM tearing eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.19" spread="0.57"/>
                    <measurement group_id="B2" value="2.25" spread="0.56"/>
                    <measurement group_id="B3" value="2.22" spread="0.48"/>
                    <measurement group_id="B4" value="2.22" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM itching eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.44" spread="0.42"/>
                    <measurement group_id="B2" value="2.43" spread="0.44"/>
                    <measurement group_id="B3" value="2.43" spread="0.44"/>
                    <measurement group_id="B4" value="2.43" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM redness of eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.32" spread="0.54"/>
                    <measurement group_id="B2" value="2.26" spread="0.58"/>
                    <measurement group_id="B3" value="2.29" spread="0.50"/>
                    <measurement group_id="B4" value="2.29" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM tearing eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.23" spread="0.50"/>
                    <measurement group_id="B2" value="2.28" spread="0.50"/>
                    <measurement group_id="B3" value="2.26" spread="0.42"/>
                    <measurement group_id="B4" value="2.26" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Rhinoconjunctivitis Quality of Life Questionnaire [RQLQ(S)] ≥3.0</title>
          <description>RQLQ(S) in subjects with baseline RQLQ[S] score ≥3.0. RQLQ(S) consists of 28 questions, each question measured on a scale of 0-6 where a higher score indicates poor quality of life. Domains: Activities (questions 1-3), Sleep (questions 4-6), Non-Nose/Eye Symptoms (questions 7-13), Practical Problems (questions 14-16), Nasal Symptoms (questions 17-20), Eye Symptoms (questions 21-24), and Emotional (questions 25-28). The overall RQLQ(S) score was calculated as the average of the mean domain scores.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.30" spread="0.80"/>
                    <measurement group_id="B2" value="4.42" spread="0.87"/>
                    <measurement group_id="B3" value="4.36" spread="0.78"/>
                    <measurement group_id="B4" value="4.36" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Daily Subject-reported AM and PM Reflective TNSS Averaged Over the Two-week Treatment Period.</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM and PM Reflective TNSS Averaged Over the Two-week Treatment Period.</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.74" spread="0.15"/>
                    <measurement group_id="O2" value="-1.75" spread="0.15"/>
                    <measurement group_id="O3" value="-0.72" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in primary outcome when compare active to placebo group. The alternative hypothesis is that there is a difference in primary outcome when compare active to placebo group. It was estimated that 200 subjects per group will provide at least 85% power to detect a difference between treatment groups of 0.7 in the change from baseline in rTNSS with a two-sided alpha level of 0.025.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value from primary outcome was adjusted at alpha=0.025.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in primary outcome when compare active to placebo group. The alternative hypothesis is that there is a difference in primary outcome when compare active to placebo group. It was estimated that 200 subjects per group will provide at least 85% power to detect a difference between treatment groups of 0.7 in the change from baseline in rTNSS with a two-sided alpha level of 0.025.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value from primary outcome was adjusted at alpha=0.025.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM and PM Instantaneous TNSS Averaged Over the 2-week Treatment Period.</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM and PM Instantaneous TNSS Averaged Over the 2-week Treatment Period.</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.04"/>
                    <measurement group_id="O2" value="-0.36" spread="0.04"/>
                    <measurement group_id="O3" value="-0.18" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dmitrienko’s tree-structured gatekeeping method was used for multiple comparisons</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.07</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dmitrienko’s tree-structured gatekeeping method was used for multiple comparisons</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM and PM Reflective TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0</title>
        <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM and PM Reflective TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0</title>
          <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.21" spread="0.13"/>
                    <measurement group_id="O2" value="-1.40" spread="0.13"/>
                    <measurement group_id="O3" value="-0.88" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dmitrienko’s tree-structured gatekeeping method was used for multiple comparisons</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1444</p_value>
            <p_value_desc>Dmitrienko’s tree-structured gatekeeping method was used for multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dmitrienko’s tree-structured gatekeeping method was used for multiple comparisons</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0124</p_value>
            <p_value_desc>Dmitrienko’s tree-structured gatekeeping method was used for multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the RQLQ(S) Overall Score at the End of the 2-week Treatment Period in Impaired Subjects With Baseline RQLQ(S) Score of ≥3.0</title>
        <description>RQLQ(S) in impaired subjects with baseline RQLQ[S] score ≥3.0. RQLQ(S) consists of 28 questions, each question measured on a scale of 0-6 where a higher score indicates poor quality of life. Domains: Activities (questions 1-3), Sleep (questions 4-6), Non-Nose/Eye Symptoms (questions 7-13), Practical Problems (questions 14-16), Nasal Symptoms (questions 17-20), Eye Symptoms (questions 21-24), and Emotional (questions 25-28). The overall RQLQ(S) score was calculated as the average of the mean domain scores.</description>
        <time_frame>Week 0-2</time_frame>
        <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the RQLQ(S) Overall Score at the End of the 2-week Treatment Period in Impaired Subjects With Baseline RQLQ(S) Score of ≥3.0</title>
          <description>RQLQ(S) in impaired subjects with baseline RQLQ[S] score ≥3.0. RQLQ(S) consists of 28 questions, each question measured on a scale of 0-6 where a higher score indicates poor quality of life. Domains: Activities (questions 1-3), Sleep (questions 4-6), Non-Nose/Eye Symptoms (questions 7-13), Practical Problems (questions 14-16), Nasal Symptoms (questions 17-20), Eye Symptoms (questions 21-24), and Emotional (questions 25-28). The overall RQLQ(S) score was calculated as the average of the mean domain scores.</description>
          <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="0.12"/>
                    <measurement group_id="O2" value="-1.44" spread="0.11"/>
                    <measurement group_id="O3" value="-0.79" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0124</p_value>
            <p_value_desc>Dmitrienko’s tree-structured gatekeeping method was used for multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM Reflective TNSS Averaged Over the 2-week Treatment Period.</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM Reflective TNSS Averaged Over the 2-week Treatment Period.</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.77" spread="0.15"/>
                    <measurement group_id="O2" value="-1.84" spread="0.15"/>
                    <measurement group_id="O3" value="-0.77" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported PM Reflective TNSS Averaged Over the 2 Week Treatment Period.</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported PM Reflective TNSS Averaged Over the 2 Week Treatment Period.</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.70" spread="0.16"/>
                    <measurement group_id="O2" value="-1.67" spread="0.16"/>
                    <measurement group_id="O3" value="-0.66" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM Instantaneous TNSS Averaged Over the 2-week Treatment Period.</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week0-2</time_frame>
        <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM Instantaneous TNSS Averaged Over the 2-week Treatment Period.</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" spread="0.15"/>
                    <measurement group_id="O2" value="-1.60" spread="0.15"/>
                    <measurement group_id="O3" value="-0.71" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported PM Instantaneous TNSS Averaged Over the 2-week Treatment Period.</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported PM Instantaneous TNSS Averaged Over the 2-week Treatment Period.</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.46" spread="0.16"/>
                    <measurement group_id="O2" value="-1.56" spread="0.15"/>
                    <measurement group_id="O3" value="-0.64" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM Reflective TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0</title>
        <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In subjects with baseline TOSS ≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM Reflective TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0</title>
          <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In subjects with baseline TOSS ≥5.0</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="0.14"/>
                    <measurement group_id="O2" value="-1.41" spread="0.14"/>
                    <measurement group_id="O3" value="-0.88" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported PM Reflective TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0</title>
        <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In subjects with baseline TOSS ≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported PM Reflective TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0</title>
          <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In subjects with baseline TOSS ≥5.0</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.21" spread="0.14"/>
                    <measurement group_id="O2" value="-1.39" spread="0.14"/>
                    <measurement group_id="O3" value="-0.88" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM Instantaneous TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0.</title>
        <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In subjects with baseline TOSS ≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM Instantaneous TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0.</title>
          <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In subjects with baseline TOSS ≥5.0</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.12" spread="0.14"/>
                    <measurement group_id="O2" value="-1.24" spread="0.14"/>
                    <measurement group_id="O3" value="-0.72" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported PM Instantaneous TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0.</title>
        <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In subjects with baseline TOSS ≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported PM Instantaneous TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0.</title>
          <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In subjects with baseline TOSS ≥5.0</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" spread="0.15"/>
                    <measurement group_id="O2" value="-1.20" spread="0.15"/>
                    <measurement group_id="O3" value="-0.74" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM and PM Instantaneous TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0.</title>
        <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In subjects with baseline TOSS ≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM and PM Instantaneous TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0.</title>
          <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In subjects with baseline TOSS ≥5.0</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.13" spread="0.14"/>
                    <measurement group_id="O2" value="-1.21" spread="0.14"/>
                    <measurement group_id="O3" value="-0.72" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported Individual AM Instantaneous NSS Averaged Over the 2-week Treatment Period</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported Individual AM Instantaneous NSS Averaged Over the 2-week Treatment Period</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.04"/>
                    <measurement group_id="O2" value="-0.40" spread="0.04"/>
                    <measurement group_id="O3" value="-0.14" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.04"/>
                    <measurement group_id="O2" value="-0.45" spread="0.04"/>
                    <measurement group_id="O3" value="-0.18" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.04"/>
                    <measurement group_id="O2" value="-0.39" spread="0.04"/>
                    <measurement group_id="O3" value="-0.21" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.04"/>
                    <measurement group_id="O2" value="-0.37" spread="0.04"/>
                    <measurement group_id="O3" value="-0.18" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported Individual PM Instantaneous NSS Averaged Over the 2-week Treatment Period</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported Individual PM Instantaneous NSS Averaged Over the 2-week Treatment Period</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.04"/>
                    <measurement group_id="O2" value="-0.40" spread="0.04"/>
                    <measurement group_id="O3" value="-0.14" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.04"/>
                    <measurement group_id="O2" value="-0.42" spread="0.04"/>
                    <measurement group_id="O3" value="-0.16" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.04"/>
                    <measurement group_id="O2" value="-0.37" spread="0.04"/>
                    <measurement group_id="O3" value="-0.16" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.04"/>
                    <measurement group_id="O2" value="-0.36" spread="0.04"/>
                    <measurement group_id="O3" value="-0.18" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported Individual AM and PM Instantaneous NSS Averaged Over the 2-week Treatment Period</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported Individual AM and PM Instantaneous NSS Averaged Over the 2-week Treatment Period</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.04"/>
                    <measurement group_id="O2" value="-0.40" spread="0.04"/>
                    <measurement group_id="O3" value="-0.14" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.04"/>
                    <measurement group_id="O2" value="-0.43" spread="0.04"/>
                    <measurement group_id="O3" value="-0.17" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.04"/>
                    <measurement group_id="O2" value="-0.38" spread="0.04"/>
                    <measurement group_id="O3" value="-0.19" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.04"/>
                    <measurement group_id="O2" value="-0.36" spread="0.04"/>
                    <measurement group_id="O3" value="-0.18" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported Individual AM Reflective Nasal Symptom Scores (NSS) Averaged Over the 2-week Treatment Period.</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported Individual AM Reflective Nasal Symptom Scores (NSS) Averaged Over the 2-week Treatment Period.</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.04"/>
                    <measurement group_id="O2" value="-0.51" spread="0.04"/>
                    <measurement group_id="O3" value="-0.18" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>runny nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.04"/>
                    <measurement group_id="O2" value="-0.51" spread="0.04"/>
                    <measurement group_id="O3" value="-0.21" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nasal itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.04"/>
                    <measurement group_id="O2" value="-0.43" spread="0.04"/>
                    <measurement group_id="O3" value="-0.20" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nasal congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.04"/>
                    <measurement group_id="O2" value="-0.38" spread="0.04"/>
                    <measurement group_id="O3" value="-0.18" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported Individual PM Reflective NSS Averaged Over the 2-week Treatment Period.</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported Individual PM Reflective NSS Averaged Over the 2-week Treatment Period.</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.04"/>
                    <measurement group_id="O2" value="-0.43" spread="0.04"/>
                    <measurement group_id="O3" value="-0.14" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.04"/>
                    <measurement group_id="O2" value="-0.45" spread="0.04"/>
                    <measurement group_id="O3" value="-0.16" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.04"/>
                    <measurement group_id="O2" value="-0.39" spread="0.04"/>
                    <measurement group_id="O3" value="-0.16" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.04"/>
                    <measurement group_id="O2" value="-0.40" spread="0.04"/>
                    <measurement group_id="O3" value="-0.20" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported Individual AM and PM Reflective NSS Averaged Over the 2-week Treatment Period.</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported Individual AM and PM Reflective NSS Averaged Over the 2-week Treatment Period.</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Intent to Treat Population. Not all subjects analyzed due to missing data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.04"/>
                    <measurement group_id="O2" value="-0.47" spread="0.04"/>
                    <measurement group_id="O3" value="-0.16" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.04"/>
                    <measurement group_id="O2" value="-0.41" spread="0.04"/>
                    <measurement group_id="O3" value="-0.18" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.04"/>
                    <measurement group_id="O2" value="-0.41" spread="0.04"/>
                    <measurement group_id="O3" value="-0.18" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.04"/>
                    <measurement group_id="O2" value="-0.39" spread="0.04"/>
                    <measurement group_id="O3" value="-0.19" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported Individual AM Instantaneous OSS in Subjects With Baseline TOSS≥5.0</title>
        <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Instantaneous OSS measures these symptoms over the previous 10 minute time interval. iTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In Subjects With Baseline TOSS≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported Individual AM Instantaneous OSS in Subjects With Baseline TOSS≥5.0</title>
          <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Instantaneous OSS measures these symptoms over the previous 10 minute time interval. iTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In Subjects With Baseline TOSS≥5.0</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>itching eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.05"/>
                    <measurement group_id="O2" value="-0.39" spread="0.05"/>
                    <measurement group_id="O3" value="-0.24" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>redness of eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.05"/>
                    <measurement group_id="O2" value="-0.38" spread="0.05"/>
                    <measurement group_id="O3" value="-0.21" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tearing eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.05"/>
                    <measurement group_id="O2" value="-0.47" spread="0.05"/>
                    <measurement group_id="O3" value="-0.27" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported Individual PM Instantaneous OSS in Subjects With Baseline TOSS≥5.0</title>
        <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Instantaneous OSS measures these symptoms over the previous 10 minute time interval. iTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In Subjects With Baseline TOSS≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported Individual PM Instantaneous OSS in Subjects With Baseline TOSS≥5.0</title>
          <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Instantaneous OSS measures these symptoms over the previous 10 minute time interval. iTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In Subjects With Baseline TOSS≥5.0</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>itching eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.05"/>
                    <measurement group_id="O2" value="-0.37" spread="0.05"/>
                    <measurement group_id="O3" value="-0.25" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>redness of eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.05"/>
                    <measurement group_id="O2" value="-0.37" spread="0.05"/>
                    <measurement group_id="O3" value="-0.27" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tearing eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.05"/>
                    <measurement group_id="O2" value="-0.45" spread="0.05"/>
                    <measurement group_id="O3" value="-0.22" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported Individual AM and PM Instantaneous OSS in Subjects With Baseline TOSS≥5.0</title>
        <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Instantaneous OSS measures these symptoms over the previous 10 minute time interval. iTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In Subjects With Baseline TOSS≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported Individual AM and PM Instantaneous OSS in Subjects With Baseline TOSS≥5.0</title>
          <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Instantaneous OSS measures these symptoms over the previous 10 minute time interval. iTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In Subjects With Baseline TOSS≥5.0</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>itching eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.05"/>
                    <measurement group_id="O2" value="-0.38" spread="0.05"/>
                    <measurement group_id="O3" value="-0.24" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>redness of eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.05"/>
                    <measurement group_id="O2" value="-0.38" spread="0.05"/>
                    <measurement group_id="O3" value="-0.24" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tearing eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.05"/>
                    <measurement group_id="O2" value="-0.46" spread="0.05"/>
                    <measurement group_id="O3" value="-0.24" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported Individual AM Reflective OSS in Subjects With Baseline TOSS ≥5.0</title>
        <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective OSS measures these symptoms over the previous 12-hour time interval. rTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In Subjects With Baseline TOSS ≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported Individual AM Reflective OSS in Subjects With Baseline TOSS ≥5.0</title>
          <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective OSS measures these symptoms over the previous 12-hour time interval. rTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In Subjects With Baseline TOSS ≥5.0</population>
          <units>participants</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>itching eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.05"/>
                    <measurement group_id="O2" value="-0.45" spread="0.05"/>
                    <measurement group_id="O3" value="-0.31" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>redness of eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.05"/>
                    <measurement group_id="O2" value="-0.42" spread="0.05"/>
                    <measurement group_id="O3" value="-0.25" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tearing eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.05"/>
                    <measurement group_id="O2" value="-0.53" spread="0.05"/>
                    <measurement group_id="O3" value="-0.33" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported Individual PM Reflective OSS in Subjects With Baseline TOSS ≥5.0</title>
        <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective OSS measures these symptoms over the previous 12-hour time interval. rTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In Subjects With Baseline TOSS ≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported Individual PM Reflective OSS in Subjects With Baseline TOSS ≥5.0</title>
          <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective OSS measures these symptoms over the previous 12-hour time interval. rTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In Subjects With Baseline TOSS ≥5.0</population>
          <units>participants</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>itching eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.05"/>
                    <measurement group_id="O2" value="-0.43" spread="0.05"/>
                    <measurement group_id="O3" value="-0.28" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>redness of eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.05"/>
                    <measurement group_id="O2" value="-0.42" spread="0.05"/>
                    <measurement group_id="O3" value="-0.28" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tearing eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.05"/>
                    <measurement group_id="O2" value="-0.54" spread="0.05"/>
                    <measurement group_id="O3" value="-0.32" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported Individual AM and PM Reflective OSS in Subjects With Baseline TOSS ≥5.0</title>
        <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective OSS measures these symptoms over the previous 12-hour time interval. rTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In Subjects With Baseline TOSS ≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported Individual AM and PM Reflective OSS in Subjects With Baseline TOSS ≥5.0</title>
          <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective OSS measures these symptoms over the previous 12-hour time interval. rTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In Subjects With Baseline TOSS ≥5.0</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>itching eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.05"/>
                    <measurement group_id="O2" value="-0.44" spread="0.05"/>
                    <measurement group_id="O3" value="-0.29" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>redness of eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.05"/>
                    <measurement group_id="O2" value="-0.42" spread="0.05"/>
                    <measurement group_id="O3" value="-0.27" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tearing eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.05"/>
                    <measurement group_id="O2" value="-0.53" spread="0.05"/>
                    <measurement group_id="O3" value="-0.32" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the RQLQ(S) Domains at the End of the 2-week Treatment Period in Impaired Subjects With Baseline RQLQ(S) Score of ≥3.0</title>
        <description>RQLQ(S) in subjects with baseline RQLQ[S] score ≥3.0. RQLQ(S) consists of 28 questions, each question measured on a scale of 0-6 where a higher score indicates poor quality of life. Domains: Activities (questions 1-3), Sleep (questions 4-6), Non-Nose/Eye Symptoms (questions 7-13), Practical Problems (questions 14-16), Nasal Symptoms (questions 17-20), Eye Symptoms (questions 21-24), and Emotional (questions 25-28). The overall RQLQ(S) score was calculated as the average of the mean domain scores.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In Impaired Subjects with Baseline RQLQ(S) Score of ≥3.0</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the RQLQ(S) Domains at the End of the 2-week Treatment Period in Impaired Subjects With Baseline RQLQ(S) Score of ≥3.0</title>
          <description>RQLQ(S) in subjects with baseline RQLQ[S] score ≥3.0. RQLQ(S) consists of 28 questions, each question measured on a scale of 0-6 where a higher score indicates poor quality of life. Domains: Activities (questions 1-3), Sleep (questions 4-6), Non-Nose/Eye Symptoms (questions 7-13), Practical Problems (questions 14-16), Nasal Symptoms (questions 17-20), Eye Symptoms (questions 21-24), and Emotional (questions 25-28). The overall RQLQ(S) score was calculated as the average of the mean domain scores.</description>
          <population>In Impaired Subjects with Baseline RQLQ(S) Score of ≥3.0</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="0.12"/>
                    <measurement group_id="O2" value="-1.44" spread="0.11"/>
                    <measurement group_id="O3" value="-0.79" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Domain 1: Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" spread="0.13"/>
                    <measurement group_id="O2" value="-1.34" spread="0.12"/>
                    <measurement group_id="O3" value="-0.70" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Domain 2: Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.49" spread="0.14"/>
                    <measurement group_id="O2" value="-1.60" spread="0.13"/>
                    <measurement group_id="O3" value="-0.83" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Domain 3: Non-Nose/Eye Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" spread="0.12"/>
                    <measurement group_id="O2" value="-1.21" spread="0.11"/>
                    <measurement group_id="O3" value="-0.67" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Domain 4: Practical Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.62" spread="0.13"/>
                    <measurement group_id="O2" value="-1.64" spread="0.12"/>
                    <measurement group_id="O3" value="-0.91" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Domain 5: Nasal Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.52" spread="0.13"/>
                    <measurement group_id="O2" value="-1.61" spread="0.12"/>
                    <measurement group_id="O3" value="-0.83" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Domain 6: Eye Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="0.13"/>
                    <measurement group_id="O2" value="-1.25" spread="0.12"/>
                    <measurement group_id="O3" value="-0.81" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Domain 7: Emotional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="0.13"/>
                    <measurement group_id="O2" value="-1.36" spread="0.12"/>
                    <measurement group_id="O3" value="-0.82" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximal Effect Over the 2-week of Double-blind Treatment Period.</title>
        <description>The time to maximal effect is defined as the number of days until the first treatment day on which the estimated difference between Ciclesonide HFA and placebo is at least 90% of the largest estimated difference. This is based on the analyses of change from baseline in the average of AM and PM reflective TNSS scores for each day. The evaluation is made separately for each dose level of Ciclesonide HFA compared to placebo.</description>
        <time_frame>Week 0-2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
            <description>160 μg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
            <description>80 μg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximal Effect Over the 2-week of Double-blind Treatment Period.</title>
          <description>The time to maximal effect is defined as the number of days until the first treatment day on which the estimated difference between Ciclesonide HFA and placebo is at least 90% of the largest estimated difference. This is based on the analyses of change from baseline in the average of AM and PM reflective TNSS scores for each day. The evaluation is made separately for each dose level of Ciclesonide HFA compared to placebo.</description>
          <units>Days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="0.18"/>
                    <measurement group_id="O2" value="8" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ciclesonide HFA Nasal Aerosol 160 μg</title>
          <description>160 μg once daily</description>
        </group>
        <group group_id="E2">
          <title>Ciclesonide HFA Nasal Aerosol 80 μg</title>
          <description>80 μg once daily</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="225"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>This study was not designed or powered for a comparison of the 80mcg dose with the 160mcg dose therefore no statistical comparisons were planned between the two active groups. Publication references to 74 and 148mcg are equivalent to 80 and 160mcg</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Respiratory Medical Director</name_or_title>
      <organization>Sunovion</organization>
      <phone>1-866-503-6351</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

